Quantinno Capital Management LP Decreases Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Quantinno Capital Management LP trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 244,052 shares of the company’s stock after selling 6,782 shares during the quarter. Quantinno Capital Management LP’s holdings in Elanco Animal Health were worth $2,955,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. CoreCap Advisors LLC bought a new stake in Elanco Animal Health in the fourth quarter valued at $29,000. Jones Financial Companies Lllp boosted its holdings in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after acquiring an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. boosted its holdings in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after acquiring an additional 3,411 shares in the last quarter. MRP Capital Investments LLC bought a new stake in Elanco Animal Health in the fourth quarter valued at $61,000. Finally, Blue Trust Inc. boosted its holdings in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after acquiring an additional 1,894 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the purchase, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. This trade represents a 10.93% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $13.24 on Tuesday. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of 33.10, a PEG ratio of 2.50 and a beta of 1.49. The firm’s 50-day moving average is $10.16 and its 200 day moving average is $11.44. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue was down 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.34 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ELAN. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a report on Monday. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Piper Sandler dropped their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Finally, Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.